We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Green Lights Medtronic’s Next-Generation Cervical Disc System

FDA Green Lights Medtronic’s Next-Generation Cervical Disc System

July 29, 2014

Medtronic said Monday it has received FDA premarket approval to launch the Prestige LP Cervical Disc system. The device, which is indicated for the treatment of single-level cervical disc radiculopathy and/or myelopathy, is the third clinically proven artificial disc in the company’s spinal portfolio.

The Prestige LP incorporates the same ball-and-trough design as the original Prestige Cervical Disc, which allows for a range of motions, including bending and rotating, Medtronic said. However, instead of requiring bone screws to attach the disc to the vertebrae, the LP attaches via two rails that press-fit into two predrilled holes created during surgery.

The LP also is made from a titanium-ceramic material that has been shown to wear more slowly and cause less MRI-interference than the previous stainless steel composition, the devicemaker said.

The U.S. launch of the Prestige LP is projected for mid-October, Medtronic spokesman Victor Rocha told Device Daily Bulletin. The LP version has been available outside the U.S. since 2004, with over 30,000 implants in 40 countries.

The PMA was based on a large prospective multicenter clinical trial of 545 patients, 280 of whom received the Prestige LP system and 265 who underwent anterior cervical discectomy and fusion, the standard care. Results at 24 months showed the Prestige LP to be a safe and effective alternative to ACDF in patients with single-level cervical disc disease.

To qualify for the Prestige LP system, patients must have failed at least six weeks of nonoperative treatment or shown signs of nerve root/spinal cord compression during treatment. — Kellen Owings

Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.

Medical Devices Submissions and Approvals Commercial Operations

Upcoming Events

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

  • 10Feb

    FDA Under the Biden Administration: What’s to Come and What It Will Mean

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 17Feb

    Effective Auditing for Manufacturing Quality

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Regeneron logo

    Regeneron’s Antibody Cocktail Shows Efficacy as COVID-19 Treatment

  • Mobile apps client cellphone cell phone

    FDA to Review Berkshire’s 510(k) Submission for Remote Drug-Delivery System

  • COVID-19

    Desidustat Improves Oxygenation for Hospitalized COVID-19 Patients

  • abbott-logo.gif

    Abbott’s Panbio COVID-19 Test Gets Additional CE Marks

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing